title: Inactivated recombinant plant virus protects dogs from a lethal challenge with canine parvovirus.
abstract: A vaccine based upon a recombinant plant virus (CPMV-PARVO1), displaying a peptide derived from the VP2 capsid protein of canine parvovirus (CPV), has previously been described. To date, studies with the vaccine have utilized viable plant chimaeric particles (CVPs). In this study, CPMV-PARVO1 was inactivated by UV treatment to remove the possibility of replication of the recombinant plant virus in a plant host after manufacture of the vaccine. We show that the inactivated CVP is able to protect dogs from a lethal challenge with CPV following parenteral immunization with the vaccine. Dogs immunized with the inactivated CPMV-PARVO1 in adjuvant displayed no clinical signs of disease and shedding of CPV in faeces was limited following CPV challenge. All immunized dogs elicited high titres of peptide-specific antibody, which neutralized CPV in vitro. Levels of protection, virus shedding and VP2-specific antibody were comparable to those seen in dogs immunized with the same VP2- peptide coupled to keyhole limpet hemocyanin (KLH). Since plant virus-derived vaccines have the potential for cost-effective manufacture and are not known to replicate in mammalian cells, they represent a viable alternative to current replicating vaccine vectors for development of both human and veterinary vaccines.
authors.affiliation: Institute for Animal Science and Health (ID-Lelystad), PO Box 65 NL-8200 AB, Lelystad, The Netherlands.
authors.forename: J P
authors.initials: JP
authors.lastname: Langeveld
authors.forename: F R
authors.initials: FR
authors.lastname: Brennan
authors.forename: J L
authors.initials: JL
authors.lastname: Martínez-Torrecuadrada
authors.forename: T D
authors.initials: TD
authors.lastname: Jones
authors.forename: R S
authors.initials: RS
authors.lastname: Boshuizen
authors.forename: C
authors.initials: C
authors.lastname: Vela
authors.forename: J I
authors.initials: JI
authors.lastname: Casal
authors.forename: S
authors.initials: S
authors.lastname: Kamstrup
authors.forename: K
authors.initials: K
authors.lastname: Dalsgaard
authors.forename: R H
authors.initials: RH
authors.lastname: Meloen
authors.forename: M M
authors.initials: MM
authors.lastname: Bendig
authors.forename: W D
authors.initials: WD
authors.lastname: Hamilton
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D002213:Capsid / Q000627:therapeutic use; D036022:Capsid Proteins; D017798:Comovirus / Q000276:immunology* / Q000528:radiation effects; D004283:Dog Diseases / Q000517:prevention & control / Q000821:virology; D004285:Dogs; D007115:Immunization Schedule; D008969:Molecular Sequence Data; D010322:Parvoviridae Infections / Q000401:mortality / Q000517:prevention & control* / Q000662:veterinary; D017993:Parvovirus, Canine / Q000276:immunology* / Q000528:radiation effects; D011994:Recombinant Proteins / Q000627:therapeutic use*; D014466:Ultraviolet Rays; D015164:Vaccines, Inactivated / Q000627:therapeutic use; D014614:Vaccines, Synthetic / Q000627:therapeutic use; D014764:Viral Proteins / Q000627:therapeutic use*; D014765:Viral Vaccines / Q000627:therapeutic use*
chemical_list: D036022:Capsid Proteins; D011994:Recombinant Proteins; D015164:Vaccines, Inactivated; D014614:Vaccines, Synthetic; D014764:Viral Proteins; D014765:Viral Vaccines